James T. Parsons
Independent ChairmanMr. James T. Parsons, MAcc, CPA, CA, serves as Independent Director of Oncolytics Biotech Inc. since June 16, 2022. He has been Chief Financial Officer of Sernova Biotherapeutics Inc (formerly known as Sernova Corp.) since October 7, 2024 and served as its Director since October 2024 until January 10, 2025. He was an Independent Director of Sernova Biotherapeutics Inc (formerly known as Sernova Corp.) since April 19, 2012 until October, 2024. With a comprehensive track record in biotech corporate finance, governance and strategic planning, Mr. Parsons is to lead Sernova's finance team and ensure the company's financial strength to support expanding objectives. Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics Inc., since August 25, 2011 until November 17, 2021. Prior to his time at Trillium, Mr. Parsons provided financial consulting services as the President of Empar Management. Mr. Parsons also served as its Principal Financial Officer and Principal Accounting Officer of Trillium Therapeutics Inc. until November 17, 2021. He served as Chief Financial Officer of Centre for Commercialization of Regenerative Medicine since January 31, 2014. Mr. Parsons had been Corporate Secretary of Trillium Therapeutics Inc. (formerly known as Stem Cell Therapeutics Corp.) since August 2011. He served as a Director of Finance at Formation Biologics Inc. (formerly AvidBiologics Inc.). Mr. Parsons has an extensive background in the life sciences industry across therapeutics, diagnostics & device companies and financial management experience. Mr. Parsons has a long and successful career in the biotechnology industry, has extensive experience with financing, product licensing, corporate governance, compliance and operational management in this arena and he has been intimately involved in the conversion by numerous biotechnology companies to the new reporting standards known as IFRS. He served at Rimon Therapeutics Ltd. and YM BioSciences Inc. He served as Vice President of Finance and Corporate Secretary at DiaMedica Therapeutics Inc. (formerly known as DiaMedica Inc.) since October 20, 2010 to May 2014. He served as an Executive Officer of Amorfix Life Sciences Ltd. since September 2010. Mr. Parsons served as Director of Finance and Administration at Trillium Therapeutics Inc. He served as the Chief Financial Officer and Corporate Secretary of Amorfix Life Sciences Ltd. from April 2005 to September 2010. He has also consulted for numerous firms including Astra Zeneca. Mr. Parsons served as the President and Chief Financial Officer of services company focused on the life sciences industry since 2003. He served as the Vice President for Finance and Administration and Chief Financial Officer of Aptose Biosciences Inc. (alternate name, Lorus Therapeutics Inc.) from March 2000 to January 10, 2003. He served as Controller and Assistant Treasurer of Timminco Limited. He is a life sciences industry consultant. He is Chairman from January 1, 2025 and has been Independent Director of DiaMedica Therapeutics Inc. (formerly known as DiaMedica Inc.) since October 23, 2015. He is a Chartered Professional Accountant and Chartered Accountant. He holds a Bachelor of Arts at Honours and a Master of Accounting from the University of Waterloo and is also a Certified Management Accountant.
Positions
- Company NameDiaMedica Therapeutics Inc.Stock CodeDMACPositionIndependent ChairmanColleagues
- DJDietrich John PaulsPresident, CEO & Director
- JTJames T. ParsonsIndependent Chairman
- SKScott KellenCFO & Corporate Secretary
- JKJulie KropChief Medical Officer
- ASAmbarish ShahChief Technology Officer
- DRDominic R. CundariChief Commercial Officer
- RMR. Michael GiuffreIndependent Director
- DJDaniel J. O'ConnorIndependent Director
- PBPhilip BathMember of Stroke Advisory Board
- Company NameSernova Biotherapeutics IncStock CodeSEOVFPositionChief Financial OfficerColleagues
- JMJonathan M. N. RigbyPresident, CEO & Director
- JLJohn L. BrooksIndependent Chairman
- MRMarylyn RigbyChief Communications Officer
- DBDavid BurkeVice President of Investor Relations
- PBPatricia BeastonSernova Biotherapeutics Inc.
- RARobert A. GabbayChairman of Clinical Advisory Board
- NCNorman C. W. WongMember of Scientific Advisory Board
- JDJannette DufourMember of Scientific Advisory Board
